412 related articles for article (PubMed ID: 18383519)
1. The molecular journey from ductal carcinoma in situ to invasive breast cancer.
Wiechmann L; Kuerer HM
Cancer; 2008 May; 112(10):2130-42. PubMed ID: 18383519
[TBL] [Abstract][Full Text] [Related]
2. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
3. Biology of ductal carcinoma in situ classification based on biologic potential.
Tsikitis VL; Chung MA
Am J Clin Oncol; 2006 Jun; 29(3):305-10. PubMed ID: 16755185
[TBL] [Abstract][Full Text] [Related]
4. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
5. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
6. The natural history of ductal carcinoma in situ of the breast: a review.
Erbas B; Provenzano E; Armes J; Gertig D
Breast Cancer Res Treat; 2006 May; 97(2):135-44. PubMed ID: 16319971
[TBL] [Abstract][Full Text] [Related]
7. Progression of heterogeneous breast tumors.
Subramanian B; Axelrod DE
J Theor Biol; 2001 May; 210(1):107-19. PubMed ID: 11343435
[TBL] [Abstract][Full Text] [Related]
8. Elevated expression of cyclooxygenase-2 in breast cancer and ductal carcinoma in situ has no correlation with established prognostic markers.
Ranger GS; Jewell A; Thomas V; Mokbel K
J Surg Oncol; 2004 Nov; 88(2):100-3. PubMed ID: 15499599
[TBL] [Abstract][Full Text] [Related]
9. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena.
Kopans DB; Rafferty E; Georgian-Smith D; Yeh E; D'Alessandro H; Moore R; Hughes K; Halpern E
Cancer; 2003 Jun; 97(12):2951-9. PubMed ID: 12784329
[TBL] [Abstract][Full Text] [Related]
10. Current controversies in the treatment of ductal carcinoma in situ of the breast.
Franceschini G; Terribile D; Magno S; Fabbri C; D'Alba P; Chiesa F; Di Leone A; Scafetta I; Masetti R
Ann Ital Chir; 2008; 79(3):151-5. PubMed ID: 18958961
[TBL] [Abstract][Full Text] [Related]
11. Molecular markers and therapeutic targets in ductal carcinoma in situ.
Boland GP; Knox WF; Bundred NJ
Microsc Res Tech; 2002 Oct; 59(1):3-11. PubMed ID: 12242692
[TBL] [Abstract][Full Text] [Related]
12. Biology and treatment of ductal carcinoma in situ.
Irvine T; Fentiman IS
Expert Rev Anticancer Ther; 2007 Feb; 7(2):135-45. PubMed ID: 17288525
[TBL] [Abstract][Full Text] [Related]
13. Pathology of ductal carcinoma in situ of the breast: current status.
Poller DN
Eur J Surg Oncol; 2001 Aug; 27(5):498-503. PubMed ID: 11504523
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of ductal carcinoma in situ of the breast.
Lagios MD
J Cell Biochem Suppl; 1993; 17G():49-52. PubMed ID: 8007709
[TBL] [Abstract][Full Text] [Related]
15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
17. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
18. Quantitative study of breast cancer progression: different pathways for various in situ cancers.
Mariuzzi L; Mombello A; Granchelli G; Rucco V; Tarocco E; Frank D; Davis J; Thompson D; Bartels H; Mariuzzi GM; Bartels PH
Mod Pathol; 2002 Jan; 15(1):18-25. PubMed ID: 11796837
[TBL] [Abstract][Full Text] [Related]
19. Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.
Mangé A; Lacombe J; Bascoul-Mollevi C; Jarlier M; Lamy PJ; Rouanet P; Maudelonde T; Solassol J
Clin Cancer Res; 2012 Apr; 18(7):1992-2000. PubMed ID: 22322670
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of allele imbalance supports atypical ductal hyperplasia lesions as direct breast cancer precursors.
Larson PS; de las Morenas A; Cerda SR; Bennett SR; Cupples LA; Rosenberg CL
J Pathol; 2006 Jul; 209(3):307-16. PubMed ID: 16604511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
